Changes of serum inflammatory factors and miR-145 expression in patients with osteoarthritis before and after treatment and their clinical value

Table 1 Sequence of primers

	Forward primer	Reverse primer
MiR-145	5'-GTCCAGTTTTCCCAGGAATCCCT- 3'	5'-GCTGTCAACATACGCTACGTAACG- 3'
U6	5'-GCGCGTCGTGAAGCGTTC- 3'	5'-GTGCAGGGTCCGAGGT- 3'

Table 2 General information

	Control group (n = 60)	Observation group (n = 83)	χ2/t	P-value
Sex, n (%)			0.846	0.358
Male	33 (55.00)	52 (62.65)
Female	27 (45.00)	31 (37.35)
Age (yr)	54.76 ± 13.64	57.48 ± 12.49	1.236	0.218
BMI (kg/m2)	23.53 ± 3.06	24.77 ± 4.14	1.964	0.052
Course of disease (yr)		3.25 ± 1.37
K-L grade, n (%)
I		31 (37.35)
II		37 (44.58)
II		15 (18.07)
VAS score
Before treatment		5.49 ± 1.27
After treatment		2.53 ± 088a
Lysholm score
Before treatment		58.45 ± 10.62
After treatment		75.26 ± 9.46a
WOMAC score
Before treatment		50.46 ± 9.14
After treatment		18.86 ± 8.38a
Disease site
Left knee		40 (48.19)
Right knee		31 (37.35)
Both knees		12 (14.46)

^aP < 0.05 vs before treatment in the same group.

Table 3 Receiver operating characteristic curve analysis of miR-145 and inflammatory factors in differentiating Kellgren-Lawrence grades

	miR-145	TNF-α	IL-6	IL-10
I-II
AUC	0.762	0.785	0.758	0.767
Critical level	1.356	142.00 ng/L	13.06 μg/L	64.37 pg/mL
Sensitivity	94.59%	59.46%	62.16%	67.57%
Specificity	51.61%	97.45%	90.32%	90.32%
II-III
AUC	0.587	0.631	0.766	0.663
Critical level	1.475	167.80 ng/L	19.62 μg/L	51.43 pg/mL
Sensitivity	32.43%	48.65%	97.30%	75.68%
Specificity	86.67%	86.68%	46.67%	60.00%

AUC: Area under the curve; TNF: Tumor necrosis factor; IL: Interleukin.